401815-98-3

Basic information

• Product Name: 2-Fluoropyridine-4-boronic acid
• Synonyms: 2-FLUOROPYRIDINE-4-BORONIC ACID;2-FLUOROPYRIDIN-4-YLBORONIC ACID;2-FLUORO-4-PYRIDINEBORONIC ACID;2-FLUORO-4-PYRIDINYLBORONIC ACID;Boronic acid, (2-fluoro-4-pyridinyl)- (9CI);2-Fluoro-4-pyridinylboronic acid ,97%;2-fluoropyridin-4-yl-4-boronic acid;4-Borono-2-fluoropyridine
• CAS NO: 401815-98-3
• Molecular Formula: C₅H₅BFNO₂
• Molecular Weight: 140.91
• EINECS: 1533716-785-6
• Product Categories: PYRIDINE;Pyridines;Boronic acid;Organoborons;Boronate Ester;Potassium Trifluoroborate
• Mol File: 401815-98-3.mol
• Article Data: 6

Chemical Properties

• Melting Point: ca 195℃
• Boiling Point: 326.8 °C at 760 mmHg
• Flash Point: 151.5 °C
• Appearance: white solid
• Density: 1.34 g/cm³
• Vapor Pressure: 8.55E-05mmHg at 25°C
• Refractive Index: 1.507
• Storage Temp.: Inert atmosphere,Store in freezer, under -20°C
• Solubility: soluble in Methanol
• PKA: 6.51±0.10(Predicted)
• CAS DataBase Reference: 2-Fluoropyridine-4-boronic acid(CAS DataBase Reference)
• NIST Chemistry Reference: 2-Fluoropyridine-4-boronic acid(401815-98-3)
• EPA Substance Registry System: 2-Fluoropyridine-4-boronic acid(401815-98-3)

Safety Data

• Statements: 36/37/38
• Safety Statements: 26-37
• Hazardous Substances Data: 401815-98-3(Hazardous Substances Data)

Usage

Chemical Properties

Solid

Uses

2-Fluoropyridine-4-boronic Acid is used to synthesize analogues of the antitubercular drug.

InChI:InChI=1/C5H5BFNO2/c7-5-3-4(6(9)10)1-2-8-5/h1-3,9-10H

Upstream product

• 688-74-4 boric acid tributyl ester 
• 22282-70-8 2-fluoro-4-iodopyridine 
• 5419-55-6 Triisopropyl borate 
• 128071-98-7 4-bromo-2-fluoropyridine 

Downstream Products

• 939437-27-1 [2-[Bis-(4-fluorophenyl)methyl]-4-(2-fluoropyridin-4-yl)thiazol-5-yl]acetic acid 
• 481048-72-0 C₁₈H₁₀ClF₂N₃ 
• 1033805-93-4 (S)-3-[4-(2-amino-6-{(S)-2,2,2-trifluoro-1-[4-(2-fluoropyridine-4-yl)phenyl]ethoxy}pyrimidin-4-yl)phenyl]-2-tert-butoxycarbonylaminopropionic acid 
• 549505-66-0 2-fluoro-4-[4-(4-fluorophenyl)-1-methyl-2-(methylsulfanyl)-1H-imidazol-5-yl]pyridine 
• 942190-67-2 3-(2-fluoro-pyridin-4-yl)-5-nitro-1-trityl-1H-indazole 
• 1187468-18-3 5-(2-fluoro-pyridin-4-yl)-thiophene-3-carboxylic acid 
• 1178886-79-7 1,1-dimethylethyl N-[4-(2-fluoropyridin-4-yl)thiazol-2-yl]-N-phenylcarbamate 
• 1196552-18-7 (R)-3-(2'-fluoro-2,4'-bipyridin-6-yl)-6-(2-(3-fluorophenyl)pyrrolidin-1-yl)imidazo[1,2-b]pyridazine 
• 1194049-78-9 C₂₃H₂₂FN₅O 
• 1206835-75-7 2-fluoro-4-[1-(4-methoxybenzyl)-3-(3-nitrophenyl)-1H-pyrazol-4-yl]pyridine 
• 1187537-80-9 C₂₂H₂₀FN₃O₄S 
• 1227175-24-7 (1H-benzo[d]imidazol-2-yl)(4-(2'-fluoro-6-methoxy-3,4'-bipyridin-2-yloxy)phenyl)methanone 
• 1227177-94-7 (1H-benzo[d]imidazol-2-yl)(4-(2'-fluoro-2-methoxy-3,4'-bipyridin-6-yloxy)phenyl)methanone 
• 1263374-77-1 N-(3-fluorobenzyl)-6-(2-fluoropyridin-4-yl)pyrazin-2-amine 

Relevant articles and documents

SERINE/THREONINE KINASE INHIBITORS

Compounds of Formula I or a stereoisomer, tautomer or pharmaceutically acceptable salt thereof are provided, which are useful for the treatment of diseases. Methods of using compounds of Formula I or a stereoisomer, tautomer or pharmaceutically acceptable salt thereof, for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such diseases, or associated pathological conditions are disclosed.

Fused pyrazole derivatives bieng protein kinase inhibitors

Compounds of Formula (I): salts or solvates or physiologically functional derivatives thereof, wherein Z is CH or N, and R1, (R2, and R4 are various substituent groups, are protein kinase inhibitors.

THERAPEUTIC COMPOUNDS

The present invention provides compounds of formula (I): pharmaceutical compositions containing the same, processes for preparing the same and their use as pharmaceutical agents.